Is your clinical partnership evolving to ensure sustained growth?
Current clinical partnership models often fail to integrate the multidisciplinary expertise of both partners, resulting in inefficient trial design and suboptimal patient recruitment.
In 'Optimising Collaboration Effectiveness in Alliance Partnerships', Tufts CSDD facilitated a roundtable of senior pharma industry executives investigating how to create a shared vision of the clinical development continuum through a new sustainable growth model that minimises inefficiencies in sponsor-CRO alliances and enables improved feasibility and access to patients.
Find out how to drive study performance with a framework that is designed to help you:
- Establish unified strategies at study outset with an evolved ‘design and execute’ approach
- Jointly evaluate new technologies in pilot studies that can accelerate timelines and generate transformational trial enhancements
- Prioritise patient centricity by keeping sites and patients engaged throughout the entire trial process
Value of alliance partnerships
Today, every large sponsor has engaged in at least one alliance partnership with a CRO. As much as 50 cents on every dollar is spent on CRO support of drug development activity, according to Ken Getz from the Tufts Center for the Study of Drug Development. “Despite decades of increasing reliance on CROs, trial success rates and overall drug development cycle times have not improved,” says Mr Getz. “And the cost to develop a successful drug continues to rise.”
Key Themes for Optimising Collaboration Effectiveness
- Evolve the partnership model from execution to design execution
- Develop a Joint Innovation Agenda
- Implement an Integrated Approach to Patient Centricity
- Build Partnership Trust
Tufts CSDD Rsearch Paper
Complete the form to Download